Who is sponsoring NCT00152659?

NCT00152659 is sponsored by University of Chicago.

What drugs are being tested in NCT00152659?

Interventions in NCT00152659: Tissue sample (procedure/screening).

What condition does NCT00152659 study?

NCT00152659 studies Epilepsy, Tumor.

Is NCT00152659 still recruiting?

NCT00152659 is currently completed. Last updated 26 April 2023.

Last reviewed 2023-04-26 · How we verify

NCT00152659

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Developing Criteria for Cortical Resections

Completed Last updated 26 April 2023

What this trial tests

trial testing Tissue sample (procedure/screening) in Epilepsy in 87 participants. Completed in 14 November 2022.

Timeline

1 September 1998

Primary endpoint
14 November 2022

14 November 2022

Quick facts

Lead sponsor	University of Chicago
Status	Completed
Study type	OBSERVATIONAL
Enrollment	87
Start date	1 September 1998
Primary completion	14 November 2022
Estimated completion	14 November 2022
Sites	1 location across United States

Drugs / interventions tested

Tissue sample (procedure/screening)

Conditions studied

Epilepsy — all drugs for Epilepsy →
Tumor — all drugs for Tumor →

Sponsor

University of Chicago

Who can join

Eligibility, any sex, with Epilepsy or Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to study how disease processes like tumors or epilepsy spread in the brain.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Epilepsy

Currently open trials in the same condition.

NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
NCT07224191 — Hippocampal Oscillations During Exploration · NA · recruiting
NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting

Other University of Chicago trials

Trials by the same sponsor.

NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
NCT07354100 — Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy · Phase 1, PHASE2 · not yet recruiting
NCT06446661 — Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia · NA · not yet recruiting
NCT07179315 — A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Tr · Phase 2 · not yet recruiting
NCT07126561 — Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00152659 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Chicago
Last refreshed: 26 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00152659.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing